Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: methylphenidate HCl (Concerta) Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108
View directory record Official record
Conditions
Healthy, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Naltrexone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1

NCT00061087
View directory record Official record
Conditions
ADHD, Opioid-Related Disorders, Cocaine Dependence
Interventions
Methylphenidate, Bupropion, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 28, 2026, 4:01 PM EDT
Not listed Phase 4 Interventional

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

NCT03781752
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Gainesville, Florida • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00253747
View directory record Official record
Conditions
ADHD, Smoking
Interventions
Osmotic-Release Methylphenidate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00499863
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate transdermal system, Placebo
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
13 Years to 17 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CTx-1301 Comparative Bioavailability Study

NCT04138498
View directory record Official record
Conditions
ADHD
Interventions
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral Differences in Effortful Control

NCT01852344
View directory record Official record
Conditions
Healthy
Interventions
Methylphenidate, Placebo, Easy Behavioral Task, Hard Behavioral Task
Drug · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

NCT01269463
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Methylphenidate Hydrochloride Extended Release Capsule, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional

Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder

NCT00181987
View directory record Official record
Conditions
ADHD, Bipolar Disorder
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Sep 28, 2026, 4:01 PM EDT
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 28, 2026, 4:01 PM EDT
Terminated Phase 3 Interventional Results available

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

NCT00516269
View directory record Official record
Conditions
Breast Cancer, Fatigue, Gastrointestinal Cancer
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

NCT00302367
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate hydrochloride, immediate release methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Severe Childhood Aggression (The TOSCA Study)

NCT00796302
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
Drug · Behavioral
Lead sponsor
Michael Aman
Other
Eligibility
6 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Learning Impairments Among Survivors of Childhood Cancer

NCT00576472
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Brain Tumors
Interventions
Methylphenidate
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
469 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2010
U.S. locations
3
States / cities
Durham, North Carolina • Charleston, South Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional Results available

Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD

NCT00780208
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Daytrana (methylphenidate patch)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Results available

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

NCT00585910
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine and OROS Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2012 · Synced Sep 28, 2026, 4:01 PM EDT
Recruiting Phase 1 Interventional

Psilocybin in Chronic Low Back Pain and Depression

NCT06355414
View directory record Official record
Conditions
Chronic Low-back Pain, Depression
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 28, 2026, 4:01 PM EDT
Terminated Phase 3 Interventional

Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors

NCT00031798
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
Interventions
methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
7
States / cities
Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Sep 28, 2026, 4:01 PM EDT
Recruiting No phase listed Observational

WAKIX® (Pitolisant) Pregnancy Registry

NCT05536011
View directory record Official record
Conditions
Pregnancy Related, Narcolepsy
Interventions
Pitolisant, Comparator Products
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
Female only
Enrollment
1,329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

NCT03292952
View directory record Official record
Conditions
ADHD
Interventions
KP415 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 2 Interventional

Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)

NCT00414921
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
clonidine, methylphenidate, placebo
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
4 Years to 6 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2009 · Synced Sep 28, 2026, 4:01 PM EDT
Not listed Phase 4 Interventional

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

NCT03781765
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Atomoxetine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Not applicable Interventional Results available

Role of Apathy in the Effectiveness of Weight Loss Interventions

NCT00548652
View directory record Official record
Conditions
Obesity, Apathy
Interventions
MOVE, medical crisis councelling, methyphenidate
Behavioral · Drug
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
21 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 28, 2026, 4:01 PM EDT
Completed Phase 4 Interventional

Use of Focalin for Fatigue in Sarcoidosis

NCT00361387
View directory record Official record
Conditions
Sarcoidosis
Interventions
d-methylphenidate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Sep 28, 2026, 4:01 PM EDT